Chart-Typ:
Zeitraum:
| Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update | SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard... ► Artikel lesen |
| Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Second Quarter 2026 Financial Results | PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026 Phase 1 trial evaluating NBD1 stabilizer... ► Artikel lesen |
| Sionna Therapeutics, Inc.: Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis | WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm... ► Artikel lesen |
| Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen |
| Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen |
| Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen |
| Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen |
| Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen |
| AbbVie-Aktie: Apogee-Übernahme beflügelt | Die AbbVie-Aktie hat den Wegfall des einstigen Blockbusters Humira deutlich besser verkraftet als viele Anleger erwartet hatten. Mit der milliardenschweren Übernahme von Apogee Therapeutics will der... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PILA PHARMA AB finden Sie auf Wallstreet Online.